

# 1 **A Set of Diagnostic Tests for Detection of Active *Babesia duncani* Infection**

2 Meenal Chand<sup>1</sup>, Pratap Vydyam<sup>1</sup>, Anasuya C. Pal<sup>1</sup>, Jose Thekkiniath<sup>1</sup>, Dounia Darif<sup>1</sup>, Zeng  
3 Li<sup>1</sup>, Jae-Yeon Choi<sup>1</sup>, Ruben Magni<sup>2</sup>, Alessandra Luchini<sup>2</sup>, Laura Tonnetti<sup>3</sup>, Elizabeth J Horn<sup>4</sup>,  
4 Danielle M Tufts<sup>5,6</sup> and Choukri Ben Mamoun<sup>1\*</sup>

5 <sup>1</sup>Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine,  
6 New Haven, CT 06520.

7 <sup>2</sup>School of Systems Biology, George Mason University, 4400 University  
8 Dr. Fairfax, VA 22030.

9 <sup>3</sup>Scientific Affairs, American Red Cross, Rockville, MD 20852.

10 <sup>4</sup>Lyme Disease Biobank, Portland, OR 97221.

11 <sup>5</sup>Department of Infectious Diseases and Microbiology, University of Pittsburgh School of  
12 Public Health, 2119 Public Health, 130 DeSoto Street, Pittsburgh, PA 15261,

13 <sup>6</sup> Department of Veterinary Tropical Diseases, University of Pretoria, South Africa.

14 \***Correspondence:** [choukri.benmamoun@yale.edu](mailto:choukri.benmamoun@yale.edu)

15 **Keywords:** Human babesiosis, Apicomplexan parasite, *Babesia duncani*, antigen capture,

16 ELISA, Antibodies, Infectious disease, Tick-borne diseases

17 **Running Title:** Diagnostic Tool for Active *Babesia duncani* Infection.

18

19 **ABSTRACT**

20 Human babesiosis is a rapidly emerging and potentially fatal tick-borne disease caused by  
21 intraerythrocytic apicomplexan parasites of the *Babesia* genus. Among the various species of  
22 *Babesia* that infect humans, *B. duncani* has been found to cause severe and life-threatening  
23 infections. Detection of active *B. duncani* infection is critical for accurate diagnosis and  
24 effective management of the disease. While molecular assays for the detection of *B. duncani*  
25 infection in blood are available, a reliable strategy to detect biomarkers of active infection has  
26 not yet been developed. Here, we report the development of the first *B. duncani* antigen  
27 capture assays that rely on the detection of two *B. duncani*-exported immunodominant  
28 antigens, BdV234 and BdV38. The assays were validated using blood samples from cultured  
29 parasites in human erythrocytes and *B. duncani*-infected laboratory mice at different  
30 parasitemia levels and following therapy. The assays display high specificity with no cross-  
31 reactivity with *B. microti*, *B. divergens*, *Babesia* MO1, or *P. falciparum*. The assay also  
32 demonstrates high sensitivity, detecting as low as 115 infected erythrocytes/ $\mu$ l of blood.  
33 Screening of 1,731 blood samples from diverse biorepositories, including previously  
34 identified Lyme and/or *B. microti* positive human samples and new specimens from field  
35 mice, showed no evidence of *B. duncani* infection in these samples. The assays could be  
36 useful in diverse diagnostic scenarios, including point-of-care testing for early *B. duncani*  
37 infection detection in patients, field tests for screening reservoir hosts, and high-throughput  
38 screening such as blood collected for transfusion.

39 **Short summary:**

40 We developed two ELISA-based assays, BdACA38 and BdACA234, for detecting *B.*  
41 *duncani*, a potentially fatal tick-borne parasite causing human babesiosis. The assays target  
42 two immunodominant antigens, BdV234 and BdV38, demonstrating high specificity (no  
43 cross-reactivity with other *Babesia* species or *Plasmodium falciparum*) and sensitivity  
44 (detecting as low as 115 infected erythrocytes/ $\mu$ l). The assays were validated using in vitro-  
45 cultured parasites and infected mice. Screening diverse blood samples showed no evidence of  
46 *B. duncani* active infection among 1,731 human and field mice blood samples collected from  
47 the north-eastern, midwestern, and western US. These assays offer potential in diverse  
48 diagnostic scenarios, including early patient detection, reservoir animal screening, and  
49 transfusion-transmitted babesiosis prevention.

50

## 51 INTRODUCTION

52 In recent years, vector-borne infectious diseases have emerged as a significant global public  
53 health concern (1). The expansion of the geographic range of the tick vectors has led to a  
54 notable increase in tick-borne diseases (TBDs), which now account for more than 75% of all  
55 reported vector-borne diseases in the United States annually (2-4). Among these tick-borne  
56 diseases is human babesiosis, an emerging infectious disease caused by intraerythrocytic  
57 apicomplexan parasites of the *Babesia* genus (5). In 2011, the disease became a US national  
58 notifiable condition in 18 states, which led to a significant increase in the number of reported  
59 cases. A recent report by the US Centers for Disease Control and Prevention (CDC)  
60 documented a rapid surge in human babesiosis cases over the past decade, 16,456 clinical  
61 cases were reported between 2011 and 2019 primarily in 37 states, with 98.2% of cases  
62 reported concentrated in 10 states (6). While ticks are the main vehicle of transmission of  
63 *Babesia* parasites, blood transfusion remains a major concern despite screening efforts.

64 To date, eight species of *Babesia* have been identified as human pathogens and documented  
65 to cause mild to severe babesiosis with some cases resulting in fatal outcomes (7). The  
66 majority of clinical cases reported to the CDC are attributed to *Babesia microti* (8, 9),  
67 whereas only a few cases of *B. duncani* babesiosis have been documented in the United  
68 States, primarily in Washington, Oregon, and California. However, it is crucial to  
69 acknowledge that some of the *B. microti* cases might be attributed to *B. duncani*. This  
70 observation underscores the significance and justifies the necessity for a new and highly  
71 sensitive diagnostic test capable of distinguishing between the two *Babesia* species. Indeed,  
72 as per the CDC Babesiosis Surveillance Report (2011-2015) in the United States, three  
73 babesiosis cases were linked to *B. duncani* in Maryland and Connecticut (10) based on  
74 serological criteria. This underscores the concern regarding the presence and potential threat

75 of *B. duncani* on the East Coast and validates the need for a new, highly sensitive diagnostic  
76 test that is specific to *B. duncani*.

77 In confirmed cases of *B. duncani* babesiosis, the parasite was found to induce fulminant and  
78 often fatal infections in both immunocompetent and immunocompromised individuals (11-  
79 14). Available data suggest that the hard tick *Dermacentor albopictus* serves as the vector for  
80 *B. duncani* (13).

81 To date, the true incidence of *B. duncani* babesiosis remains unknown. Accurate  
82 determination of the true prevalence of *B. duncani* babesiosis is challenging due to the  
83 absence of specific and reliable diagnostic tests that can determine active infection. Over the  
84 years, various diagnostic techniques including microscopy, serological tests like  
85 immunofluorescence assay (IFA), immunoblot and enzyme-linked immunosorbent assay  
86 (ELISA), and nucleic acid-based tests such as nested PCR, reverse transcription-polymerase  
87 chain reaction (RT-PCR), and transcription-mediated amplification (TMA), have been  
88 employed to detect *Babesia* infections. Morphologically, *B. duncani*-infected red blood cells  
89 (RBCs) are indistinguishable from those infected with *B. microti* or other *Babesia* species and  
90 bear resemblance to the ring-stage forms of *Plasmodium falciparum*, the causative agent of  
91 severe human malaria. Therefore, microscopy cannot be reliably used to diagnose *B. duncani*  
92 active infection in a blood sample. With the exception of cases confirmed by both  
93 microscopy and PCR (14-19), most unverified cases attributed to this parasite have relied on  
94 serological assays, which cannot reliably distinguish between past and active infections. A  
95 2018 publication by Scott and Scott summarized reports by physicians and naturopathic  
96 physicians of 1119 cases of *B. duncani* between 2011 and 2017 in Canada, with most cases  
97 occurring in the Pacific Coast region (20). However, no positive blood smears or details  
98 about the sensitivity or specificity of the serological and molecular assays used were  
99 described in that report. Furthermore, no appropriate controls were included in these studies.

100 Therefore, these claims warrant further validation, which could be facilitated by sharing  
101 blood samples with established biorepositories and large-scale blood screening in different  
102 geographic areas in the US. Nucleic acid-based detection techniques are indeed more specific  
103 and sensitive and have been effective in identifying positive *B. microti* blood samples.  
104 Nevertheless, in some instances, these techniques have been shown to detect residual parasite  
105 DNA or RNA even after the parasite has been eliminated (21, 22). Recent studies using  
106 microscopic examination of blood samples from *B. microti*-infected animals treated with  
107 drugs that cleared the infection demonstrated the presence of residual DNA after treatment  
108 with antibabesial drugs (22). Studies using *B. microti*-infected blood revealed that antigen  
109 detection assays, which rely on the detection of highly abundant and often immunodominant  
110 secreted antigens of the parasite, exhibit a stronger correlation with active *B. microti* infection  
111 compared to Nucleic Acid-detection assays (23). Therefore, efforts to develop similar assays  
112 for the detection of active infections by other *Babesia* species could be an invaluable resource  
113 to estimate the true incidence of babesiosis caused by each of the *Babesia* species that cause  
114 infection in humans. This is particularly important in light of the rapid environmental changes  
115 impacting the transmission of these diseases and other TBDs (24, 25).

116 A significant breakthrough in the field of *B. duncani* biology emerged with the  
117 establishment of the first continuous *in vitro* culture system of *B. duncani* in human  
118 erythrocytes (26-28). Furthermore, the recent sequencing and annotation of the parasite's  
119 genome (29) made it possible to apply a multi-faceted approach that incorporates genomic,  
120 transcriptomic, and proteomic analyses to identify unique and species-specific proteins that  
121 are exported by the parasite from infected RBCs into the host plasma.

122 In this study, we report the discovery of two highly reliable biomarkers for active *B.*  
123 *duncani* infection. *Babesia duncani*-specific antigen capture assays (BdACAs) that detect  
124 these antigens were developed and exhibit high sensitivity, are capable of detecting as low as

125 115 parasites/ $\mu$ l of blood and can distinguish active infections from past exposures, and can  
126 distinguish between *B. microti* and *B. duncani* to provide accurate species infections,  
127 important for public health.

## 128 **MATERIALS AND METHODS**

129 **Ethics statement--** All animal experiments described in this study followed the Yale  
130 University institution guidelines for the care and use of laboratory animals and were  
131 approved by the Institutional Animal Care and Use Committee at Yale University (protocol  
132 number 2023-07689).

133 ***Babesia duncani* infection in mice--** C3H/HeJ or SCID mice (C.B-17/IcrHsd-Prkdcscid) 5-6  
134 week, female mice from Jackson laboratories were infected by injecting  $1 \times 10^6$  or  $1 \times 10^7$  *B.*  
135 *duncani* WA-1 strain or *B. microti* LabS1 strain, respectively by infected erythrocytes  
136 intravenously (IV) from the stock mouse. Blood samples were collected at different time  
137 points by a retro-orbital bleed or cardiac puncture, and parasitemia was monitored by light  
138 microscopy of Giemsa-stained blood smears. Where indicated, plasma or serum was  
139 separated from whole blood by centrifugation at 6000g for 10 min, and packed mouse RBC  
140 (mRBC) was lysed with 1% saponin. Hemolysate and parasite pellets were collected after  
141 centrifugation at 9300g for 10 min at 4°C.

142 ***Babesia duncani* in vitro culture--** *Babesia duncani* WA-1 parasites were cultured  
143 continuously in human erythrocytes in DMEM-F12 media (28), as described previously (26).  
144 (Included in Supplementary methods).

145 **Isolation of extracellular vesicles from plasma, culture supernatant, and hemolysate --**  
146 Extracellular membrane vesicles containing protein cargo released from the parasite were  
147 isolated from supernatant/plasma and hemolysate of *B. duncani* *in vitro* and *in vivo* culture by  
148 EXO Quick ULTRA EV isolation kit (EQUltra-20A-1) following the user manual. Where  
149 indicated, vesicles were also isolated by the ultracentrifugation method, as mentioned  
150 previously (30). Briefly, 1.5 ml of human RBC (hRBC) and mRBC samples (uninfected and  
151 *B. duncani* infected plasma/serum or supernatant and hemolysate) were sequentially



152 centrifuged at 500g for 30 min, followed by 16,000g for 45 min. These samples were then  
153 centrifuged at 120,000g for 14h at 4°C using a Sorvall MTX 150 micro-ultracentrifuge with  
154 an S52-ST swinging bucket rotor (Thermo Fisher) and ultracentrifuge pellet (Up/UHp) and  
155 ultracentrifugation supernatant (Us/UHs) fractions were collected (31).

156 **Cloning, expression, and purification of recombinant proteins--** Plasmid DNA constructs  
157 for BdV234 and BdV38 were synthesized by GenScript, Inc., NJ. Details description of  
158 protein expression and purification provided in the supplementary methods.

159 **Immunodetection of BdV234 and BdV38--** Polyclonal antibodies raised in rabbits  
160 (Cocalico Biologicals, Inc., PA) against the indicated *B. duncani* proteins were purified and  
161 used for the immunodetection analysis as described in detail (32). Briefly, supernatant (S),  
162 hemolysate (H), and parasite pellet (P) fractions collected either from *B. duncani in vitro*  
163 culture in hRBC (18% parasitemia) or *B. duncani* infected (24% parasitemia) or uninfected  
164 mRBCs were mixed with 4X Laemmli sample buffer (3:1 ratio), boiled at 80°C for 5 min and  
165 separated on 4-20% Mini-protean gels (Bio-Rad, P4568093). The gels were then transferred  
166 onto nitrocellulose membranes (Bio-Rad, 1620115), probed with anti-BdV234 and BdV38  
167 primary antibodies (1:250 dilution) and goat-anti-rabbit horseradish peroxidase (HRP)-  
168 conjugated IgG Ab (1: 5000 dilution, (Thermo Fisher, 31466). Blots were developed by  
169 Super signal<sup>TM</sup> West Pico PLUS chemiluminescent substrate (Thermo Fisher, 34577) and  
170 imaged using the LI-COR Odyssey-Fc imaging system.

171 **Immunofluorescence assay (IFA)--** Immunofluorescence assay was performed as reported  
172 previously (30, 32) and described briefly in the supplementary methods.

173 **BdACA using *B. duncani in vitro* culture supernatant and hemolysate fractions—**  
174 *Babesia duncani* antigen capture sandwich ELISAs were performed as described earlier (22,  
175 23), with few modifications. Briefly, 96-well plates were coated with 5µg/ml of capture Abs

176 (BdV234 and BdV38) and incubated for 2h at room temperature, followed by blocking with  
177 5% BSA in PBST (0.05% Tween-20) at 37°C for 1h. Plates were then incubated overnight at  
178 4°C with either (1) BdV38 and BdV234 recombinant protein (100 ng/well), (2) a 1 in 10  
179 dilution of *B. duncani in vitro* culture supernatant, hemolysate, and whole blood, or (3)  
180 plasma/serum (heat-inactivated for 30 min at 56°C), hemolysate and whole blood from  
181 uninfected or *B. duncani* infected C3H/HeJ mice. Whole blood samples from American Red  
182 Cross (ARC), Lyme Disease Biobank (LDB), and field-derived mouse samples were  
183 incubated similarly. The plates were then washed four times with PBST, and 5 µg/ml  
184 biotinylated detection Ab (BdV234 and BdV38) were added and incubated at room  
185 temperature for 2h. Following this, plates were washed four times with PBST and incubated  
186 with HRP conjugated streptavidin antibody in 1:5000 dilution at room temperature for 1h,  
187 followed by washing and incubation with 50 µl 3,3',5,5' tetramethylbenzidine (TMB)  
188 substrate for 7 min in the dark. The reaction was stopped by adding 50 µl of 0.1N HCl, and  
189 the Optical Density at 450 nm was measured using a BioTek Synergy Mx plate reader.

190 **Detection of BdV234 and BdV38 antigens in hemolysate from drug-treated *B. duncani***  
191 ***in vitro* culture or infected mouse blood--** *In vitro* *B. duncani* culture with an initial  
192 parasitemia of 1% (cultured in 5% hematocrit with DMEMF-12 containing hRBCs) was  
193 exposed to tafenoquine (SML0396, Sigma Aldrich) at 1x IC<sub>50</sub> (3 µM) and 2x IC<sub>50</sub> (6 µM)  
194 concentrations for three generations. Both untreated and tafenoquine treated parasite cultures  
195 were collected at specified time points (0, 3, 6, 12, 24, 36, 48, 60, and 72 hours post  
196 treatment), lysed with 1% saponin, and the resulting hemolysates were used for ELISA.  
197 Untreated infected and uninfected hRBCs were included as controls. Similarly, hemolysates  
198 were prepared from blood from 12 C3H/HeJ (3 male, 3 female) mice infected with a high  
199 dose of *B. duncani* (10<sup>6</sup> parasites) and used in ELISA to detect BdV234 and BdV38. Six of  
200 these mice were treated with tafenoquine for 5 days (DPI 3-7), and the remaining six were

201 treated with vehicles (PEG400). Vehicle-treated and uninfected mice hemolysates were used  
202 as controls.

203 **Genomic DNA extraction and Real-Time PCR--** To further confirm the presence or  
204 absence of *B. duncani* DNA in infected blood, qPCR analyses were conducted as previously  
205 reported (33). Briefly, blood from *B. duncani in-vitro* culture and *B. duncani* infected mouse  
206 at various parasitemia levels were collected at specific time points post-infection, followed by  
207 gDNA isolation by the DNeasy Blood and Tissue kit (Qiagen, 69504). The isolated genomic  
208 DNA were used to amplify the *B. duncani* internal transcribed spacer (ITS) sequence in its  
209 nuclear rRNA (18s-rRNA) by using BdITS1-F 5'-GCTTCCTAACCCGAGACCAA-3' and  
210 BdITS1-R 5'-CACTGGCGGGGTGAAAAGTA-3' primers (34). The reaction mixture  
211 contained 1× advanced universal SYBR green super mix (1725270; Bio-Rad), 1 µl of each  
212 primer (10 µM), and 2 µl of template DNA.

213 **Collection of biological samples used for screening *B. duncani* antigen/infection--** Two  
214 hundred human whole blood samples were obtained from the American Red Cross (ARC), of  
215 which 100 samples were positive for *B. microti* infection as detected by transcriptionally  
216 mediated amplification (TMA) positive and the remaining 100 samples were TMA negative  
217 for *B. microti*, the samples were collected in areas endemic for *B. microti*. (Connecticut,  
218 Delaware, Massachusetts, Maryland, Maine, Minnesota, New Hampshire, New Jersey, New  
219 York, Pennsylvania, Virginia, Vermont). Additionally, 770 whole blood samples were  
220 obtained from the Lyme Disease Biobank (LDB) with 317 samples enrolled with signs and  
221 symptoms of early Lyme disease and 282 controls as previously described (35) and were  
222 collected from East Hampton, Martha's Vineyard, and Wisconsin (2014- 2020). Similarly 171  
223 samples were collected from the west coast (California), including 11 enrolled with early  
224 Lyme disease, 10 controls, and 150 with persistent Lyme symptoms. Whole blood samples  
225 were also obtained from 761 white-footed mice (*Peromyscus leucopus*), a prominent

226 reservoir host of *B. microti*, (unscreened) that were collected from western Pennsylvania,  
227 USA, and used in this study.

## 228 RESULTS

229 **Identification of *B. duncani* secreted antigens.** The genome of *B. duncani* has been  
230 extensively studied and characterized. Its annotation identified 4222 proteins, of which 479  
231 are predicted to be members of the parasite's secretome (29). To identify proteins exported  
232 by the parasite into the host red blood cell and/or host environment, we used a Nanotrap-  
233 based proteomics approach (36, 37) on hemolysate (H) and secreted (S) fractions collected  
234 from a culture of *B. duncani*-infected human erythrocytes as shown in **Fig. 1A**. Mass  
235 spectrometry analysis identified 27 proteins in the S fraction (**Table 1**) and 39 proteins in the  
236 H fraction. Of these exported proteins, BdV234 and BdV38 were selected based on their  
237 peptide abundance, high expression levels of their encoding genes as determined by RNAseq,  
238 and predicted antigenicity profiles (**Table 1**). The genes encoding these two proteins were  
239 cloned into the pGEX 6p-1 and pET21a (+) expression vectors, respectively, and the encoded  
240 recombinant proteins were expressed in *E. coli*, purified on glutathione Sepharose high-  
241 performance (BdV234) and Ni-NTA agarose (BdV38) affinity columns and used to generate  
242 specific polyclonal antibodies in rabbits. The antibodies were then affinity-purified and  
243 evaluated for their specificity using recombinant proteins as well as total extracts from a  
244 culture of *B. duncani*-infected erythrocytes. The resulting affinity-purified anti-BdV234 and  
245 anti-BdV38 antibodies were used to detect the expression and cellular distribution of the  
246 native proteins in the supernatant (S), hemolysate (H), or pellet (P) fractions from cultures of  
247 *B. duncani*-infected human erythrocytes and control uninfected human erythrocytes (**Fig.**  
248 **1B**). Consistent with the export of these proteins, immunoblot analyses identified the native  
249 BdV234 and BdV38 in all three fractions while no signal could be detected in the fractions  
250 isolated from the uninfected erythrocytes (**Fig. 1B**). We then assessed the cellular distribution  
251 of the same antigens in mice infected with *B. duncani*. Interestingly, whereas the antigens  
252 could be readily detected in the H and P fractions prepared from mouse blood collected from

253 *B. duncani*-infected C3H/HeJ mice, the signal from the plasma (Pl) fraction was very weak,  
254 likely the result of dilution in the large volume of plasma collected from infected animals  
255 (**Fig. 1B**). Additionally no signal could be detected from the Pl, H, or P fractions prepared  
256 from blood collected from uninfected mice, further confirming the specificity of the  
257 antibodies raised against these proteins (**Fig. 1B**).

258

259 **Evidence of vesicular-mediated secretion of BdV234 and BdV38 from *B. duncani*-**  
260 **infected erythrocytes.** Recent studies in *B. microti* and *B. divergens* have demonstrated that  
261 several proteins of these parasites' are actively exported by using vesicular-mediated export  
262 mechanisms (30, 38). To assess the mode of export of BdV234 and BdV38, the culture S and  
263 H fractions of *B. duncani*-infected human erythrocytes, as well as the Pl and H fractions of *B.*  
264 *duncani*-infected mice were subjected to ultracentrifugation at 120,000 x g for 14h at 4°C to  
265 separate the soluble (Us/UHs) and vesicle-associated membrane (Up/UHp) fractions. These  
266 resulting fractions were then analyzed by immunoblotting using anti-BdV234 and anti-  
267 BdV38 antibodies to assess the presence or absence of the antigens. As shown in **Fig. 1C**, the  
268 proteins were primarily found associated with the Up/UHp fractions in both human and  
269 mouse infected samples (**Fig. S1-A**), indicating that once exported from the infected  
270 erythrocytes, these antigens are associated with vesicles. This association was further  
271 validated using the ExoQuick® vesicle isolation system, which was used to separate the  
272 supernatant fraction (Es/EHs) from the vesicle-rich pellet fraction (Ev/EHv) on plasma,  
273 supernatant, and hemolysate fractions collected from uninfected or *B. duncani*-infected blood  
274 (**Fig. S1-B**). As shown in **Fig. 1D**, both antigens were detected in the vesicle fractions (E<sub>v</sub> or  
275 HE<sub>v</sub>) from the S, H, and Pl fractions obtained from *B. duncani*-infected human and mouse  
276 RBCs, respectively. As a control, no signal could be detected in similar fractions prepared  
277 from blood collected from uninfected human erythrocytes *in vitro* or uninfected C3H/HeJ

278 mice (**Fig. 1D**). Together these data demonstrate that BdV234 and BdV38 are exported by *B.*  
279 *duncani*-infected erythrocytes through a vesicular-mediated mechanism.

280

281 **Cellular localization of selected *B. duncani* secreted proteins.** In order to investigate the  
282 localization and cellular distribution of BdV234 and BdV38 secretory proteins in *B. duncani*,  
283 immunofluorescence assays (IFA) were conducted on uninfected or *B. duncani*-infected  
284 human erythrocytes by using affinity-purified BdV234 and BdV38 antibodies from rabbit  
285 sera. Anti-rabbit Alexafluor-488 was used for the detection of BdV234 and BdV38, and  $\alpha$ -  
286 Band III antibody was used as a membrane marker for human RBCs. Interestingly, BdV234  
287 was not only found to be localized inside the parasites but was also found in the host  
288 erythrocytes displaying punctate vesicular staining (**Fig. 2**), which indicating that this GPI-  
289 anchored protein is secreted by the parasite into the host cytosol. On the other hand, BdV38  
290 was found to be localized primarily within the parasites. The rabbit pre-immune sera served  
291 as a control in our IFA, and no localization signal with BdV234 and BdV38 was observed  
292 other than the nucleus and RBC membrane (**Fig. 2**).

293

294 **Development of *B. duncani* antigen capture Assays BdACAs.** The discovery that BdV234  
295 and BdV38 could be readily detected in the hemolysate and environment of *B. duncani*-  
296 infected erythrocytes led us to investigate the use of these two proteins as biomarkers of an  
297 active *B. duncani* infection. We used the anti-BdV234 and anti-BdV38 antibodies to design  
298 an antigen capture sandwich ELISA assay (BdACA) to detect the exported proteins in *B.*  
299 *duncani*-infected blood (**Fig. 3A**). The BdACA assays, one for each antigen, were initially  
300 optimized by employing two-fold serial dilutions of recombinant BdV234 and BdV38  
301 proteins to generate a standard curve. The ELISA data was graphed with optical density

302 against known antigen concentrations to obtaining sigmoidal curves (**Fig. 3B**). To further  
303 validate the assays for native proteins at the cellular level, an *in vitro* culture of *B. duncani*-  
304 infected human erythrocytes at 18% parasitemia with 5% hematocrit was prepared, and the  
305 supernatant and hemolysate fractions were collected, subjected to two-fold serial dilutions,  
306 and used to detect the exported antigens. From our findings, both BdV234 and BdV38  
307 effectively identified the presence of total parasite proteins that were secreted into the culture  
308 supernatant and established a positive correlation with the percentage of parasitemia counted  
309 by microscopy (**Fig. 3C**). In addition, when the assays were conducted on the culture  
310 hemolysate samples, we observed a comparable correlation accompanied by a marginal rise  
311 in the absorbance values (**Fig. 3D**). In both assay conditions, we observed nearly undetectable  
312 levels of the proteins when using the supernatant and hemolysates from cultures of uninfected  
313 human RBCs. We extended the BdACA validation into the established *in vivo* mouse model,  
314 utilizing serum and plasma from *B. duncani*-infected mice (with ~24% parasitemia) (**Fig. 3E**),  
315 along with the H fractions (**Fig. 3F**). We observed robust detection of the parasite antigens  
316 when probing the mouse hemolysate fractions with both antibodies, while the levels were  
317 merely undetectable in the serum or plasma fractions (**Fig. 3E**). As expected, there was no  
318 detection in the serum, plasma, or hemolysate fractions from uninfected mice.

319

320 **High sensitivity of BdACAs for detection of *B. duncani* infection.** The sensitivity of the  
321 BdACAs was assessed using a culture of *B. duncani* at  $\sim 9 \times 10^6$  *B. duncani*-iRBCs per ml,  
322 which was subsequently subjected to two-fold dilutions and allowed to proliferate for 24h in  
323 culture. For the comparison of BdACA with qPCR, we isolated the genomic DNA from the  
324 same samples and used it for PCR detection of the *B. duncani* 18s rRNA (**Fig. 4A**). The H  
325 fractions from the same cultures were further used to evaluate the sensitivity of the BdACAs.  
326 The Bd38ACA could detect as low as  $1 \times 10^3$  iRBCs, while Bd234ACA could detect as low



327 as  $2 \times 10^3$  iRBCs (**Fig. 4B-C**). No reactivity was observed in uninfected human RBCs, as  
328 expected. The limit of blank (LOB) marked the threshold above which all values were  
329 considered positive, while the limit of detection (LOD) for Bd38ACA and Bd234ACA was  
330 determined to be 3 x of LOB ( $OD_{450}=0.3$ ). The sensitivity of BdACA was also assessed to  
331 establish the minimum detectable level of parasitemia. A 1 ml of *B. duncani in vitro* culture  
332 with an initial parasitemia of 0.5% (5% hematocrit) was allowed to grow over time, and  
333 parasitemia was monitored. After isolating the hemolysate (1 ml), genomic DNA extraction  
334 was performed to facilitate quantitative polymerase chain reaction (qPCR) analysis (**Fig. 4D**).  
335 The BdACA assay employed 5 microliters per well alongside the previously mentioned  
336 hemolysate volume. Our findings demonstrated that the BdACA method effectively  
337 identified parasitemia levels as low as 0.5%, consistent with the expected sensitivity.  
338 Additionally, as the secretion of antigens increased over time, our assays could detect more  
339 secreted antigens (**Fig. 4E-F**). Similarly, to validate the sensitivity of the assay *in vivo*  
340 samples, blood was collected from day post-infection (dpi) 0-7 from C3H/HeJ mice.  
341 Genomic DNA isolated from parasites at different time points was used in qPCR using *B.*  
342 *duncani* 18s rRNA forward and reverse primers that detected parasites as early as 0-dpi (**Fig.**  
343 **4G**), while Bd38ACA and Bd234ACA could detect the antigens as early as 2 and 3 dpi,  
344 respectively (**Fig. 4H-I**).

345

346 **BdV38 and BdV234 as biomarkers for evaluating antibabesial treatment efficacy.** An  
347 ideal biomarker of active *Babesia* infection is one whose levels show an excellent positive  
348 correlation with parasitemia levels and does not remain in the blood following clearance of  
349 infection due to drug treatment. To assess whether BdV38 and BdV234 meet these criteria,  
350 BdACAs were conducted on *in vitro B. duncani* cultures under both untreated and drug-

351 treated conditions. Parasite cultures with 1 % parasitemia were initially inoculated and  
352 collected at 12h intervals over a 72h period (three parasite erythrocytic lifecycles) following  
353 treatment with either vehicle control (DMSO) or tafenoquine (TQ) at 3  $\mu$ M (1x IC<sub>50</sub>) and 6  
354  $\mu$ M (2x IC<sub>50</sub>). The samples were assessed for parasitemia detection in both conditions  
355 through microscopic analysis of Giemsa-stained blood smears. Observations from Giemsa-  
356 stained blood smears at stipulated time intervals of post-inoculation displayed continuous  
357 parasite growth until 72h (**Fig. 5A**) . The decline in % parasitemia over time and the  
358 inhibitory impact of 1x and 2x IC<sub>50</sub> of tafenoquine were evident, detecting parasitemia as low  
359 as 0.05% and 0.1% at 48h compared to the untreated (UT) parasites, which reached  
360 approximately 10% after 72h post-inoculation (**Fig. 5A**). The detection of BdV38 from the  
361 total parasite lysate positively correlated with the viability of the parasite over time in  
362 untreated (UT) samples (**Fig. 5B**). In contrast, the curve declined over time and reached a  
363 plateau after 48h with tafenoquine treatment (1x or 2x) (**Fig. 5B**). For post-drug treatment, as  
364 tafenoquine cleared the parasites from the culture, the total absorbance showed nearly no  
365 difference compared to the uninfected RBC lysate. Upon qPCR analysis of the same samples  
366 to assess parasite detection, the presence of *B. duncani* DNA was indicated in both the  
367 untreated and treated conditions at stipulated time intervals. However, a clear difference was  
368 observed between the uninfected and infected samples (**Fig. 5C**). Similarly, we used whole  
369 blood samples from uninfected and *B. duncani*-infected (10<sup>6</sup>) mice that were treated with  
370 tafenoquine (TQ) or vehicle. Blood samples were tested to assess parasite growth by  
371 microscopy (**Fig. 5D**), and BdV38ACA was used to detect BdV38 secretion that declined  
372 after 7 dpi once the parasites were cleared by the drug treatment (**Fig. 5E**). qPCR results  
373 suggested DNA remained in circulation even after the parasites were cleared (**Fig. 5F**). Thus,  
374 the Bd38ACA assay reliably detected only active infections. Similarly we tested these *in vivo*

375 and *in vivo* samples with anti-BdV234 antibody and found the similar results as with BdV38  
376 (Fig. S3).

377

378 **Bd38ACA and Bd234ACA are highly specific assays for *B. duncani* detection.** To assess  
379 the specificity of the BdACA assays, we tested blood samples infected with other *Babesia*  
380 species and similar apicomplexan parasites, such as *P. falciparum* from *in vitro* culture as  
381 well as from animal hosts. We also compared the sensitivity of BdACA from uninfected and  
382 *B. microti* ( $10^6$ ) infected mouse blood. Uninfected and *B. duncani*-infected mouse blood was  
383 used as a control. Our *in vivo* results indicated that Bd38ACA (Fig. 6A) and Bd234ACA  
384 (Fig. 6C) are highly specific for *B. duncani*-secreted proteins compared to *B. microti*.  
385 Similarly, the assays were conducted on *in vitro* blood samples from different cultures of *B.*  
386 *divergens* (Rouen87 strain), *Babesia MOI*, or *P. falciparum* (3D7 strain), each with 10%  
387 parasitemia grown in human erythrocytes. Our result indicated that Bd38ACA (Fig. 6B) and  
388 Bd234ACA (Fig. 6D) only detect the respective proteins secreted by *B. duncani*, and no  
389 signal above the lower limit detection of OD 0.3 could be detected in these samples.

390

391 **Blood screening using Bd38ACA.** To evaluate the effectiveness of BdACA as screening  
392 tools for detecting active *B. duncani* infections, we employed the Bd38ACA assay to screen  
393 1,731 whole blood specimens from diverse locations across the US. These encompassed 200  
394 human whole blood samples (100 *B. microti*-positive and 100 *B. microti*-negative) from the  
395 American Red Cross (ARC); 770 human whole blood samples from the Lyme Disease  
396 Biobank (LDB), previously screened for Lyme disease and *B. microti*; and 761 whole blood  
397 samples from white-footed mice collected from Western Pennsylvania (Fig. 7A). In this  
398 study, the lower limit of detection (LOD;  $OD_{450} = 0.3$ ) was defined as thrice of the LOB

399 (lower limit of blank), which corresponds to a *B. duncani* parasitemia of 0.3% (**Fig. 7B**). All  
400 1,731 samples, analyzed in this study, showed OD<sub>450</sub> values below 0.6, which when  
401 compared to the standard curve for *B. duncani* parasitemia levels corresponds to parasitemia  
402 levels below 0.55% (**Fig. 7A**). Of these 1731 samples, 8 had OD<sub>450</sub> values between 0.31 and  
403 0.59. Among the 761 white-footed mouse samples, 756 showed signals below the LOD and 5  
404 samples showed signals above the LOD but below an OD<sub>450</sub> of 0.35 (< than 2x LOD).  
405 Similarly, out of the 770 Lyme Disease Biobank samples, 3 showed signals above the LOD  
406 with OD<sub>450</sub> of 0.31, 0.49 and 0.59. The 8 samples with OD<sub>450</sub> signals above the LOD using  
407 the BdV38-based detection assay, were further confirmed to be within this same range when  
408 tested using the BdV234ACA assay (not shown), suggesting that these samples either carry  
409 *B. duncani* at parasitemia levels below 0.5% or the BdV38 and BdV234 assays detect  
410 antigens from other closely related pathogens. To gain further insights into the source of the  
411 signals in these samples (N=9, one ARC30 sample also included), PCR-based amplification  
412 analyses were conducted using the primer pairs listed in Table 2. Using primers designed to  
413 be specific for *B. duncani* (specific to *HSP-70*, *CelTos*, and *BdV38* genes), *B. microti*  
414 (specific to *BmITS* and *Bm GPII2* genes), *B. divergens* (specific to *AMA-1* gene) and *B.*  
415 *MOI* (specific to the helicase gene), our PCR analyses showed that these samples do not  
416 contain DNA from these species (**Fig. S4-S5**). To assess whether these samples contain DNA  
417 from other *Babesia* species, we selected samples with the highest OD<sub>450</sub> among these for  
418 PCR analysis using a previously reported primer pair (39) that amplifies a 200 bp of the 18 S  
419 rRNA gene from multiple *Babesia* species (**Fig. 6A**). The nine samples included 1 from  
420 ARC, 3 from Lyme Biobank and 5 from field mice. As shown in **Fig. 6 B**, six of the 9  
421 samples tested positive by PCR. Sequencing of the 200 bp PCR product revealed sequences  
422 with 98 to 100% identity to 18S rRNA genes from *Babesia* species of Clade VI (*B. divergens*,  
423 *capreoli*, *B. odocoilei*, and *B. venatorum*) (**Table 3**). To further evaluate these data, a new

424 primer set was designed to bind to conserved regions of the 18S rRNA genes of *Babesia*  
425 species and amplify a 736 bp. Using this primer set against all 9 samples, we found 5 (field  
426 mice) samples to be positive by PCR. However, sequencing of the fragments failed to  
427 identify a specific species at more than 90% sequence identify (**Fig. S6 C-D**). Together these  
428 data suggest that the 8 samples may contain new species of *Babesia* or closely related  
429 organisms that the BdACAs can also detect. However, the exact identity of these new species  
430 could not be determined due to limited amount of material available for large scale genomic  
431 analyses.

## 432 DISCUSSION

433 Herein, we report the development of the first antigen capture assays, BdACAs, for the  
434 detection of active *B. duncani* infection. The assays detect the presence of *B. duncani*-  
435 secreted antigens BdV38 (31 kDa) or BdV234 (27 kDa) in blood samples from infected  
436 cultures or animals with high sensitivity and specificity. The BdACAs exhibit a remarkable  
437 sensitivity in detecting these secreted *B. duncani* antigens from as little as a single drop of  
438 blood, equivalent to  $1.6 \times 10^7$  red blood cells, in both human and mouse samples.  
439 Furthermore, the assay specifically distinguishes *B. duncani* infections when tested against  
440 other human babesiosis-causing parasites (*B. microti*, *B. divergens* (Rouen87), *Babesia* MO1)  
441 or related protozoan species (*P. falciparum*) that causes human malaria. These assays,  
442 therefore, open up new possibilities for efficient and convenient diagnosis of *B. duncani*  
443 infection, ensuring timely intervention and improved healthcare outcomes. The versatility of  
444 this assay makes it useful in various setups, including point-of-care (POC) tests in clinics or  
445 at home. Its potential applications include confirming acute *B. duncani* infection, screening  
446 clinical samples, and ensuring the safety of blood supplies at blood donation centers, thereby  
447 preventing transfusion-transmitted babesiosis. Additionally, it offers a valuable tool for  
448 conducting epidemiological surveys to detect *B. duncani* infection in humans and reservoir  
449 hosts. Given the urgent need for improved diagnostic tests to combat vector borne or  
450 transfusion-transmitted babesiosis, as seen with other *Babesia* sp. in the USA, the  
451 development of this assay represents a significant stride toward achieving that goal (40, 41)  
452 and the first report of an ELISA based antigen capture assay for *B. duncani*.

453 The current strategies employed for the detection of subclinical infections of  
454 intraerythrocytic parasites suffer from notable limitations. Microscopy, although widely used,  
455 exhibits low sensitivity and specificity, making it challenging to differentiate between various  
456 species of *Babesia* and other apicomplexan parasites, such as *Plasmodium*. Serological tests

457 such as immunofluorescence assays (IFA) lack reliability in distinguishing between acute and  
458 chronic infections. On the other hand, PCR based assays that show high sensitivity to detect  
459 parasite DNA can detect the DNA even after the infection has been cleared, as observed in  
460 the case of *B. microti* (22). An ineffective diagnostic tool also hampers the proper  
461 understanding of the epidemiological distribution of the parasite in its reservoir hosts.

462 One key advantage leveraged in our approach is the use of an in culture- in mouse (ICIM)  
463 model system of *B. duncani* (42) infection, which allowed us to systematically examine  
464 different aspects of our assay, including optimizing the assay using various sample types such  
465 as hemolysate, supernatant, whole blood, plasma, and serum. Additionally, the recent  
466 comprehensive genome analysis of *B. duncani* by Singh *et. al.* (29) shed light on the  
467 abundance and nature of proteins, epigenome, and transcriptome analysis identified classes of  
468 candidate virulence factors, antigens for diagnosis of active infection, and several attractive  
469 drug targets. Studies in *B. microti* have shown that secreted proteins are excellent biomarkers  
470 for the detection of active parasite infection (43, 44). These findings led to the development  
471 of antigen capture assays (ACAs) for the detection of the secreted antigen BmGPI12 (22, 23).

472 Here, we have used an integrated approach consisting of genomic, transcriptomic, and  
473 proteomic analyses to identify secreted proteins of *B. duncani*, which could be suitable as  
474 biomarkers of active infection from different fractions (S, H, and P) (**Table 1**). Among the  
475 pool of exported proteins, BdV234 and BdV38 were specifically chosen due to their  
476 substantial peptide abundance and notably elevated expression levels (**Table 1**). We reasoned  
477 that those proteins with higher abundance and containing signal sequences were  
478 predominantly destined for the extracellular space, where they could play a crucial role in  
479 eliciting cell signaling and facilitating communication between host and parasite to promote  
480 infection propagation. To our surprise, our initial attempts to detect BdV234 and BdV38  
481 directly from the plasma or serum of *B. duncani*-infected mice were unsuccessful. However,

482 by employing ultracentrifugation and the Exo-Quick approach, we were able to purify  
483 extracellular vesicles (EVs) that contained these parasite proteins. The EVs containing these  
484 *B. duncani* proteins may play a crucial role in the trafficking and delivery of these proteins,  
485 allowing them to be expressed on the outer membrane of infected RBCs similar to that  
486 reported for *B. microti* (30, 38). Our IFA results, from *in vitro* *B. duncani*-infected parasites,  
487 further support the cellular distribution of these proteins. Further investigation is warranted to  
488 explore the precise mechanism by which these proteins are sorted and packaged into EVs, as  
489 well as their specific role in mediating their transport to the surface of infected RBCs.  
490 Understanding the molecular processes involved in this vesicular transport machinery will  
491 contribute to our overall comprehension of *B. duncani* pathogenesis and host-parasite  
492 interactions.

493 This study assessed the field suitability of Bd38ACA by screening a diverse array of human  
494 and mouse whole blood samples. The assay exhibited minimal cross-reactivity with both  
495 human and field-derived white-footed mouse samples. However, a subset (0.4%) of samples  
496 showed low reactivity with Bd38ACA, at levels significantly lower in comparison to the  
497 positive control samples. Subsequent PCR analysis confirmed the absence of *B. duncani*  
498 parasites in these samples but the exact organisms, likely a species closely related to *B.*  
499 *duncani*, that cause the cross-reactivity detected in the BdACA assays remain to be further  
500 characterized.

501 In conclusion, our findings demonstrate that BdACA is a reliable diagnostic assay for the  
502 detection of active *B. duncani* infection. It is suitable for large-scale screening of the blood  
503 supply and further optimization of the assay is warranted to test uninfected and infected  
504 human blood samples and compare with the current method (NAT assays) for blood  
505 screening. The development of such a diagnostic tool is a significant step forward in the fight



506 against *B. duncani* and can significantly improve the accuracy and efficiency of diagnosis,  
507 treatment, and surveillance of this emerging tick-borne disease.

508

509 **Figure legends:**

510 **Figure 1. Identification and detection of *B. duncani* secreted antigens.** (A) Schematic  
511 presentation for qualitative analysis of *B. duncani* secretome by nano-trap-based proteomics  
512 approach (NTPA) utilizing ultracentrifugation and a tandem mass spectrometry analysis  
513 (MS/MS) to identify *Babesia duncani* secreted proteins. (B) Immuno detection of secreted  
514 BdV234 and BdV38 antigens from *B. duncani* infected human *in vitro* and mouse (ihRBCs,  
515 imRBCs) culture supernatant (S), plasma (Pl), hemolysate (H) and parasite pellet (P) and  
516 uninfected RBC (uhRBC, umRBC) with their corresponding protein size. (C) Western blot  
517 analysis to detect BdV234 and BdV38 secreted antigens from extracellular vesicular fractions  
518 obtained by ultracentrifugation approach using *B. duncani*-infected human and mouse RBCs.  
519 After ultracentrifugation, the soluble fraction Us and the pellet fraction Up were collected  
520 from the culture supernatant/plasma, and UHs and UHp fractions were obtained from the  
521 hemolysate. Our data indicated that these proteins containing extracellular vesicles  
522 accumulate in the pellet fraction Up/UHp from *in vitro* as well as from *in vivo*  
523 supernatant/plasma or hemolysate. These measurements were conducted under both infected  
524 (I) and uninfected (U) conditions. (D) Detection of BdV234 and BdV38 proteins from  
525 extracellular vesicle supernatant (Es), and vesicle-rich pellet (Ev) fractions from both *B.*  
526 *duncani* infected and uninfected *in vitro* culture supernatant and mouse plasma. Similar,  
527 detection of protein from extracellular vesicles (EHs) and pellet (EHv) fractions of both  
528 human and mouse hemolysate samples.

529

530 **Figure 2. Immunofluorescence assay for the detection of subcellular localization of *B.***  
531 ***duncani* secreted proteins.** Immunofluorescence staining of BdV234 and BdV38 proteins  
532 using rabbit polyclonal anti-BdV234 and BdV38 antibodies. Samples were subsequently,

533 stained with an anti-rabbit secondary antibody conjugated with Alexa Fluor (AF)-488  
534 (Green) in *B. duncani* -infected human RBCs. Anti-Band-III monoclonal antibody (Red) was  
535 used to label the human erythrocyte plasma membrane, and DAPI (Blue) was used to stain  
536 the parasite nucleus (DNA). The green fluorophore reveals both the localization and  
537 distribution of the parasite-secreted proteins within or outside the host red blood cell. Immune  
538 Sera: rabbit sera collected after injection of recombinant BdV234 and BdV38 recombinant  
539 proteins, and preimmune sera: same rabbit sera collected before injection of recombinant  
540 proteins. Differential Interference Contrast (DIC). Scale bars, 5µm.

541

542 **Figure 3. Development and detection of active *B. duncani* infection by BdACA.** (A)  
543 Schematic representation of the ELISA-based *B. duncani* antigen capture assay (BdACA). *B.*  
544 *duncani* secreted antigens (recombinant proteins) BdV234 and BdV38 were used as specific  
545 biomarkers for the detection of parasite infection. Respective antigen-specific polyclonal  
546 antibodies (ASPA) were used as both capture and biotinylated-detection antibodies to detect  
547 the *B. duncani* secreted antigens (BdV234 and BdV38). (B) A standard curve with  
548 recombinant BdV234 and BdV38 proteins was tested in two-fold serial dilutions. (C-F) A  
549 dose-response curve showing the absorbance at 450 nm (y-axis) plotted against two-fold  
550 serial diluted supernatant (C) and hemolysate (D) obtained from *in vitro* cultures of *B.*  
551 *duncani* infected human erythrocytes and from *B. duncani* infected mouse plasma/serum (E)  
552 and hemolysate (F) along with uninfected hRBC/mRBC as controls (black and grey). The  
553 specific polyclonal antibodies were used to detect BdV234 (pink, triangle) and BdV38 (blue,  
554 circle) antigens. The error bars represent the standard deviation (SD), calculated using  
555 GraphPad Prism 9.3 software. All samples were analyzed in two independent experiments in  
556 triplicates.

557

558 **Figure 4. BdACA shows high sensitivity to detect *B. duncani*-infected human and mouse**

559 **red blood cells. (A)** Scatter plot illustrates the correlation between cycle threshold values (Cq)

560 and the number of *B. duncani*-infected red blood cells (iRBCs). Cq values were obtained

561 through q-PCR analysis using Bd ITS (18S rRNA) primers on isolated genomic DNA from

562 indicated parasites. The graph plotted using Cq values on the Y-axis against the number of

563 iRBCs on the X-axis, from an *in vitro* *B. duncani* culture. Horizontal dotted line represents

564 the cut-off threshold, with numerical values on the x-axis depicting the quantity of infected

565 RBCs, where 'x 10<sup>3</sup>' denotes a scale of 1000 for RBC count. **(B-C)** Detection of BdV38 **(B)**

566 and BdV234 **(C)** secreted antigens from *B. duncani*-infected human RBCs from *in vitro*

567 culture samples with different dilutions of parasites as shown in the bar graph, and the %

568 parasitemia was counted by Giemsa stain (black scatter plot). **(D-F)** *Babesia duncani* *in vitro*

569 culture, diluted to 0.5% parasitemia (5% hematocrite), was incubated at 37°C. Samples were

570 collected over time, beginning zero hour post-inoculation to 48 hours. Genomic DNA was

571 isolated from these samples and quantified using qPCR targeting the 18S rRNA gene **(D)**.

572 Similarly, hemolysate fractions were prepared to detect the BdV38 **(E)** and BdV234 **(F)**

573 antigens from these samples. **(G-I)** For sensitivity analysis from *in vivo* samples, C3H/HeJ

574 mice were inoculated with 10<sup>6</sup> parasites and monitored. Parasites were collected at various

575 time points (0-7 dpi) post-infection and subjected for quantification of the 18S rRNA gene by

576 qPCR **(G)**. BdACAs detection of BdV38 **(H)** and BdV234 **(I)** antigens from *B. duncani*

577 infected mouse erythrocytes after post-inoculation. Blood from uninfected mice was used as

578 control. The dashed lines show the limit of blank (LOB, gray) and the limit of detection

579 (LOD, black), respectively. NTC: non template control, UC: uninfected control, iRBC:

580 infected red blood cells, uRBC: uninfected red blood cells.

581

582 **Figure 5. Detection of BdV38 antigen after Tafenoquine treatment of *B. duncani***  
583 **cultures. (A and D)** Percent parasitemia over time from *B. duncani in vitro* culture (A) or  
584 mouse infected with *B. duncani* (D) in vehicale (PEG-400) untreated (UT) or tafenoquine  
585 treated (1x IC<sub>50</sub> and 2x IC<sub>50</sub> TQ samples over time. (B and E) Bd38ACA detection of BdV38  
586 antigen in *B. duncani in vitro* culture hemolysate (B) and *B. duncani* 10<sup>6</sup> infected mouse  
587 hemolysate (E) in untreated or tafenoquine treated samples. (C and F) genomic DNA  
588 isolated from parasites from *in vitro* (C) or mice (F) at different time points pre and post  
589 tafenoquine treatment were subjected to *B. duncani* 18S rRNA quantitative PCR. Graphs  
590 denote the Cq values over time.

591 **Figure 6. *In vitro* and *In vivo* specificity of BdACAs for *Babesia* antigens.** Bd38ACA (A-  
592 B) or Bd234ACA (C-D) were performed on uninfected (Bd-U) or *B. duncani*-infected (Bd-I)  
593 (24% parasitemia) C3H/HeJ mouse hemolysate and uninfected (Bm-U) or *B. microti*-infected  
594 (Bm-I) (70% parasitemia) CB17 SCID mouse hemolysate (A and C). *In vitro* culture  
595 hemolysate from uninfected (RBC) or *B. duncani* (Bd) (10 % parasitemia), *B. divergens*  
596 Rouen87 (B.div) (10 % parasitemia), *B. MO1* (10 % parasitemia) (MO1), and *P. falciparum*  
597 (*Pf3D7*) (10% parasitemia) infected samples (B and D). *Bd- Babesia duncani*, *Bm- Babesia*  
598 *microti*, *B.div- Babesia divergens rouen87*, *Pf3D7- Plasmodium falciparum 3D7*, I-infected,  
599 U- uninfected, cF12-complete DMEM-F12, and cRPMI-complete RPMI media. The gray  
600 dashed lines show the limit of blank (LOB,) and black dashed line show the limit of  
601 detection (LOD) (OD<sub>450</sub>=0.3). respectively. Error bars showing the standard deviation (SD)  
602 which were calculated by GraphPad Prism 9.3.

603

604 **Figure 7. Bd38ACA screening of ARC, LDB human patient samples, and untested field-**  
605 **derived white-footed mouse samples. (A)** Screening of known positive and negative

606 *Babesia* patient samples, Lyme positive and negative samples, and unknown infection from  
607 field-derived white-footed mouse samples with Bd38ACA. One hundred *B. microti*  
608 transcription-mediated amplification (TMA)-positive human patient samples (blue open  
609 upward triangle), 100 TMA-negative human patient samples (blue closed inverted triangle)  
610 from American Red Cross (ARC), 478 Lyme disease positive (orange open circle), and 292  
611 control samples (orange closed circle) from Lyme Disease Biobank (LDB) samples (770  
612 samples) and 761 unknown field mice samples (purple open diamond) were tested. Each  
613 sample was used in triplicates. **(B)** Two fold serially diluted *B. duncani* infected human  
614 RBC hemolysate (ihRBC; gray bar graph) were used as positive controls to compare the  
615 samples OD<sub>450</sub> in correlation with % parasitemia. Black and red dash lines show the limit of  
616 blank (LOB) and limit of detection (LOD) respectively. Error bars showing the standard  
617 deviation (SD) were calculated using GraphPad Prism 9.3 software. (\*) showing OD<sub>450</sub> of  
618 patient samples that were slightly positive for Bd38ACA.

619

620 **Author contributions**

621 MC, PV, DD, LZ, JC, and AP: Investigation, methodology, formal analysis, visualization,  
622 writing original draft, review, and editing. SW: Sample collection and analysis. CB:  
623 Conceptualization, supervision, funding acquisition, project administration, writing original  
624 draft, review, and editing. All authors have read and agreed to the published version of the  
625 manuscript. All authors contributed to the article and approved the submitted version.

626

627 **Funding**

628 The research described herein was supported by the Global Lyme Alliance Foundation. CBM  
629 research is also supported by NIH grants AI138139, AI123321, AI152220 and AI153100,  
630 and AI136118, the Steven and Alexandra Cohen Foundation (Lyme 62 2020), and The  
631 Blavatnik Family Foundation.

632

633 **Acknowledgments**

634 We thank the American Red Cross and the Lyme Disease Biobank for providing the blood  
635 samples used in this study.

636 **References**

- 637 1. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. 2008. Global  
638 trends in emerging infectious diseases. *Nature* 451:990-3.
- 639 2. Eisen RJ, Eisen L, Beard CB. 2016. County-Scale Distribution of *Ixodes scapularis* and  
640 *Ixodes pacificus* (Acari: Ixodidae) in the Continental United States. *J Med Entomol* 53:349-  
641 86.
- 642 3. Eisen RJ, Kugeler KJ, Eisen L, Beard CB, Paddock CD. 2017. Tick-Borne Zoonoses in the  
643 United States: Persistent and Emerging Threats to Human Health. *Ilar j* 58:319-335.
- 644 4. Rosenberg R, Lindsey NP, Fischer M, Gregory CJ, Hinckley AF, Mead PS, Paz-Bailey G,  
645 Waterman SH, Drexler NA, Kersh GJ, Hooks H, Partridge SK, Visser SN, Beard CB,  
646 Petersen LR. 2018. Vital Signs: Trends in Reported Vectorborne Disease Cases - United  
647 States and Territories, 2004-2016. *MMWR Morb Mortal Wkly Rep* 67:496-501.
- 648 5. Renard I, Ben Mamoun C. 2021. Treatment of Human Babesiosis: Then and Now. *Pathogens*  
649 10.
- 650 6. Swanson M PA, Williamson J, Montgomery S. 2023. Trends in Reported Babesiosis Cases —  
651 United States, 2011–2019.
- 652 7. Puri A, Bajpai S, Meredith S, Aravind L, Krause PJ, Kumar S. 2021. *Babesia microti*:  
653 Pathogen Genomics, Genetic Variability, Immunodominant Antigens, and Pathogenesis.  
654 *Front Microbiol* 12:697669.
- 655 8. Vannier E, Gewurz BE, Krause PJ. 2008. Human babesiosis. *Infect Dis Clin North Am*  
656 22:469-88, viii-ix.
- 657 9. Vannier EG, Diuk-Wasser MA, Ben Mamoun C, Krause PJ. 2015. Babesiosis. *Infect Dis Clin*  
658 *North Am* 29:357-70.
- 659 10. Gray EB HB. 2019. Babesiosis Surveillance — United States, 2011–2015. *MMWR Surveill*  
660 *Summ* 68:1–11.
- 661 11. O'Connor KE, Kjemtrup AM, Conrad PA, Swei A. 2018. An Improved PCR Protocol For  
662 Detection of *Babesia duncanI* In Wildlife and Vector Samples. *J Parasitol* 104:429-432.



- 663 12. Conrad PA, Kjemtrup AM, Carreno RA, Thomford J, Wainwright K, Eberhard M, Quick R,  
664 Telford SR, 3rd, Herwaldt BL. 2006. Description of *Babesia duncani* n.sp. (Apicomplexa:  
665 Babesiidae) from humans and its differentiation from other piroplasms. *Int J Parasitol* 36:779-  
666 89.
- 667 13. Swei A, O'Connor KE, Couper LI, Thekkiniath J, Conrad PA, Padgett KA, Burns J,  
668 Yoshimizu MH, Gonzales B, Munk B, Shirkey N, Konde L, Ben Mamoun C, Lane RS,  
669 Kjemtrup A. 2019. Evidence for transmission of the zoonotic apicomplexan parasite *Babesia*  
670 *duncani* by the tick *Dermacentor albipictus*. *Int J Parasitol* 49:95-103.
- 671 14. Quick RE, Herwaldt BL, Thomford JW, Garnett ME, Eberhard ML, Wilson M, Spach DH,  
672 Dickerson JW, Telford SR, 3rd, Steingart KR, Pollock R, Persing DH, Kobayashi JM,  
673 Juranek DD, Conrad PA. 1993. Babesiosis in Washington State: a new species of *Babesia*?  
674 *Ann Intern Med* 119:284-90.
- 675 15. Herwaldt BL, Kjemtrup AM, Conrad PA, Barnes RC, Wilson M, McCarthy MG, Sayers MH,  
676 Eberhard ML. 1997. Transfusion-transmitted babesiosis in Washington State: first reported  
677 case caused by a WA1-type parasite. *J Infect Dis* 175:1259-62.
- 678 16. Bloch EM, Herwaldt BL, Leiby DA, Shaieb A, Herron RM, Chervenak M, Reed W, Hunter  
679 R, Ryals R, Hagar W, Xayavong MV, Slemenda SB, Pieniazek NJ, Wilkins PP, Kjemtrup  
680 AM. 2012. The third described case of transfusion-transmitted *Babesia duncani*. *Transfusion*  
681 52:1517-22.
- 682 17. Kjemtrup AM, Conrad PA. 2000. Human babesiosis: an emerging tick-borne disease. *Int J*  
683 *Parasitol* 30:1323-37.
- 684 18. Fritz CL, Kjemtrup AM, Conrad PA, Flores GR, Campbell GL, Schriefer ME, Gallo D, Vugia  
685 DJ. 1997. Seroepidemiology of emerging tickborne infectious diseases in a Northern  
686 California community. *J Infect Dis* 175:1432-9.
- 687 19. Persing DH, Herwaldt BL, Glaser C, Lane RS, Thomford JW, Mathiesen D, Krause PJ,  
688 Phillip DF, Conrad PA. 1995. Infection with a babesia-like organism in northern California. *N*  
689 *Engl J Med* 332:298-303.

- 690 20. Scott JD, Scott CM. 2018. Human Babesiosis Caused by *Babesia duncani* Has Widespread  
691 Distribution across Canada. *Healthcare (Basel)* 6.
- 692 21. Healy GR, Speilman A, Gleason N. 1976. Human babesiosis: reservoir in infection on  
693 Nantucket Island. *Science* 192:479-80.
- 694 22. Thekkiniath J, Mootien S, Lawres L, Perrin BA, Gewirtz M, Krause PJ, Williams S, Doggett  
695 JS, Ledizet M, Ben Mamoun C. 2018. BmGPAC, an Antigen Capture Assay for Detection of  
696 Active *Babesia microti* Infection. *J Clin Microbiol* 56.
- 697 23. Gagnon J, Timalisina S, Choi JY, Chand M, Singh P, Lamba P, Gaur G, Pal AC, Mootien S,  
698 Marcos LA, Ben Mamoun C, Ledizet M. 2022. Specific and Sensitive Diagnosis of *Babesia*  
699 *microti* Active Infection Using Monoclonal Antibodies to the Immunodominant Antigen  
700 BmGPI12. *J Clin Microbiol* 60:e0092522.
- 701 24. Caminade C, McIntyre KM, Jones AE. 2019. Impact of recent and future climate change on  
702 vector-borne diseases. *Ann N Y Acad Sci* 1436:157-173.
- 703 25. Gilbert L. 2021. The Impacts of Climate Change on Ticks and Tick-Borne Disease Risk.  
704 *Annu Rev Entomol* 66:373-388.
- 705 26. Abraham A, Brasov I, Thekkiniath J, Kilian N, Lawres L, Gao R, DeBus K, He L, Yu X, Zhu  
706 G, Graham MM, Liu X, Molestina R, Ben Mamoun C. 2018. Establishment of a continuous in  
707 vitro culture of *Babesia duncani* in human erythrocytes reveals unusually high tolerance to  
708 recommended therapies. *J Biol Chem* 293:19974-19981.
- 709 27. Kumari V, Pal AC, Singh P, Mamoun CB. 2022. *Babesia duncani* in Culture and in Mouse  
710 (ICIM) Model for the Advancement of *Babesia* Biology, Pathogenesis, and Therapy. *Bio*  
711 *Protoc* 12.
- 712 28. Singh P, Pal AC, Mamoun CB. 2022. An Alternative Culture Medium for Continuous In  
713 Vitro Propagation of the Human Pathogen *Babesia duncani* in Human Erythrocytes.  
714 *Pathogens* 11.
- 715 29. Singh P, Lonardi S, Liang Q, Vydyam P, Khabirova E, Fang T, Gihaz S, Thekkiniath J,  
716 Munshi M, Abel S, Ciampossin L, Batugedara G, Gupta M, Lu XM, Lenz T, Chakravarty S,  
717 Cornillot E, Hu Y, Ma W, Gonzalez LM, Sánchez S, Estrada K, Sánchez-Flores A, Montero


- 718 E, Harb OS, Le Roch KG, Mamoun CB. 2023. Babesia duncani multi-omics identifies  
719 virulence factors and drug targets. *Nat Microbiol* 8:845-859.
- 720 30. Thekkiniath J, Kilian N, Lawres L, Gewirtz MA, Graham MM, Liu X, Ledizet M, Ben  
721 Mamoun C. 2019. Evidence for vesicle-mediated antigen export by the human pathogen  
722 Babesia microti. *Life Sci Alliance* 2.
- 723 31. Baranyai T, Herczeg K, Onódi Z, Voszka I, Módos K, Marton N, Nagy G, Mäger I, Wood  
724 MJ, El Andaloussi S, Pálincás Z, Kumar V, Nagy P, Kittel Á, Buzás EI, Ferdinandy P, Giricz  
725 Z. 2015. Isolation of Exosomes from Blood Plasma: Qualitative and Quantitative Comparison  
726 of Ultracentrifugation and Size Exclusion Chromatography Methods. *PLoS One*  
727 10:e0145686.
- 728 32. Chand M, Choi JY, Pal AC, Singh P, Kumari V, Thekkiniath J, Gagnon J, Timalisina S, Gaur  
729 G, Williams S, Ledizet M, Mamoun CB. 2022. Epitope profiling of monoclonal antibodies to  
730 the immunodominant antigen BmGPI12 of the human pathogen Babesia microti. *Front Cell*  
731 *Infect Microbiol* 12:1039197.
- 732 33. Wang Y, Zhang S, Wang J, Rashid M, Wang X, Liu X, Yin H, Guan G. 2022. Nested qPCR  
733 assay to detect Babesia duncani infection in hamsters and humans. *Parasitol Res* 121:3603-  
734 3610.
- 735 34. Wang G, Wormser GP, Zhuge J, Villafuerte P, Ip D, Zeren C, Fallon JT. 2015. Utilization of  
736 a real-time PCR assay for diagnosis of Babesia microti infection in clinical practice. *Ticks*  
737 *Tick Borne Dis* 6:376-82.
- 738 35. Horn EJ, Dempsey G, Schotthoefer AM, Prisco UL, McArdle M, Gervasi SS, Golightly M,  
739 De Luca C, Evans M, Pritt BS, Theel ES, Iyer R, Liveris D, Wang G, Goldstein D, Schwartz  
740 I. 2020. The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples  
741 from the East Coast and Upper Midwest of the United States. *J Clin Microbiol* 58.
- 742 36. Tamburro D, Fredolini C, Espina V, Douglas TA, Ranganathan A, Ilag L, Zhou W, Russo P,  
743 Espina BH, Muto G, Petricoin EF, 3rd, Liotta LA, Luchini A. 2011. Multifunctional core-  
744 shell nanoparticles: discovery of previously invisible biomarkers. *J Am Chem Soc*  
745 133:19178-88.

- 746 37. Magni R, Luchini A, Liotta L, Molestina RE. 2019. Analysis of the Babesia microti proteome  
747 in infected red blood cells by a combination of nanotechnology and mass spectrometry. *Int J*  
748 *Parasitol* 49:139-144.
- 749 38. Beri D, Rodriguez M, Singh M, Liu Y, Rasquinha G, An X, Yazdanbakhsh K, Lobo CA.  
750 2022. Identification and characterization of extracellular vesicles from red cells infected with  
751 Babesia divergens and Babesia microti. *Front Cell Infect Microbiol* 12:962944.
- 752 39. Quorllo BA, Archer NR, Schreeg ME, Marr HS, Birkenheuer AJ, Haney KN, Thomas BS,  
753 Breitschwerdt EB. 2017. Improved molecular detection of Babesia infections in animals using  
754 a novel quantitative real-time PCR diagnostic assay targeting mitochondrial DNA. *Parasit*  
755 *Vectors* 10:128.
- 756 40. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. 2011.  
757 Transfusion-associated babesiosis in the United States: a description of cases. *Ann Intern Med*  
758 155:509-19.
- 759 41. Fang DC, McCullough J. 2016. Transfusion-Transmitted Babesia microti. *Transfus Med Rev*  
760 30:132-8.
- 761 42. Pal AC, Renard I, Singh P, Vydyam P, Chiu JE, Pou S, Winter RW, Dodean R, Frueh L,  
762 Nilsen AC, Riscoe MK, Doggett JS, Ben Mamoun C. 2022. Babesia duncani as a Model  
763 Organism to Study the Development, Virulence, and Drug Susceptibility of Intraerythrocytic  
764 Parasites In Vitro and In Vivo. *J Infect Dis* 226:1267-1275.
- 765 43. Elton CM, Rodriguez M, Ben Mamoun C, Lobo CA, Wright GJ. 2019. A library of  
766 recombinant Babesia microti cell surface and secreted proteins for diagnostics discovery and  
767 reverse vaccinology. *Int J Parasitol* 49:115-125.
- 768 44. Luo Y, Jia H, Terkawi MA, Goo YK, Kawano S, Ooka H, Li Y, Yu L, Cao S, Yamagishi J,  
769 Fujisaki K, Nishikawa Y, Saito-Ito A, Igarashi I, Xuan X. 2011. Identification and  
770 characterization of a novel secreted antigen 1 of Babesia microti and evaluation of its  
771 potential use in enzyme-linked immunosorbent assay and immunochromatographic test.  
772 *Parasitol Int* 60:119-25.




# Figure 1


**A**




**B**




**C**









**D**



**Figure 2**












# Figure 3






# Figure 4




**Figure 5**


**A**




**D**




**B**




**E**



**C**




**F**




**Figure 6**


**A**




**B**



**C**




**D**




**Figure 7**

**A**



**B**



**Table 1.** List of proteins identified in the supernatant of *B. duncani*-infected human erythrocytes using nano trap technology.

Accession ID	Description	Protein FDR Confidence	Number of Peptides	Number of amino acids	MW [kDa]	RNAseq (TPM)#
BdWA1_000818-T1	Actin, putative	High	5	376	41.9	6836.72
BdWA1_000589-T1	phosphatidylinositol-4-phosphate 5-kinase, putative	High	4	1074	121.8	278.21
BdWA1_002814-T1	Thioredoxin domain Thioredoxin, conserved site Thioredoxin-like superfamily	High	4	490	54.4	1398.21
BdWA1_000266-T1	hypothetical protein, conserved	High	3	498	57.4	21.68
BdWA1_001049-T1	Hsp20/alpha-crystallin family, putative	High	3	177	20.1	8294.36
BdWA1_002869-T1	hypothetical protein, conserved	High	3	215	24.6	778.09
BdWA1_003373-T1	hypothetical protein	High	1	127	12.5	8199.71
BdWA1_001726-T1	RAP domain/Core histone H2A/H2B/H3/H4, putative	High	3	132	14.5	26809.25
<b>BdWA1_002223-T1</b>	<b>BdV234</b> (GPI-anchored protein BdGPI8)	<b>High</b>	<b>2</b>	<b>242</b>	<b>27.2</b>	<b>1655.60</b>
BdWA1_001531-T1	hypothetical protein	High	3	375	41.4	4774.64
BdWA1_003044-T1	heat shock protein 70 precursor, putative	High	2	644	70.6	2621.88
<b>BdWA1_001730-T1</b>	<b>BdV38</b> (putative EF-hand domain)	<b>High</b>	<b>1</b>	<b>292</b>	<b>33</b>	<b>1426.92</b>
BdWA1_001385-T1	40S ribosomal protein S3 protein, putative	High	1	224	25	1702.62
BdWA1_000947-T1	heat shock protein 90	High	2	713	82.3	4798.62
BdWA1_001677-T1	Sodium: dicarboxylate symporter family, putative	High	1	789	89.4	272.46
BdWA1_002995-T1	NAC domain-containing protein, putative	High	1	159	17.1	575.40
BdWA1_001746-T1	hypothetical protein, conserved	High	1	374	42.8	667.65
BdWA1_001707-T1	heat shock protein 70 precursor, putative	High	2	654	71.9	0.98
BdWA1_001359-T1	histone H3, putative	High	2	136	15.4	21963.75
BdWA1_002631-T1	Porin domain superfamily	High	1	298	32.9	572.95
BdWA1_000088-T1	hypothetical protein	High	1	601	68.4	17.86
BdWA1_001694-T1	Enolase,N-terminal domain / Enolase, C-terminal TIM barrel domain-containing protein, putative	Medium	1	442	47.6	4.71
BdWA1_000240-T1	BdGPI17	Medium	1	618	69.8	1674.59
BdWA1_000444-T1	myosin A	Medium	1	827	92.4	7.04
BdWA1_002345-T1	cytochrome c oxidase subunit 2, putative	Medium	1	168	19.1	353.85
BdWA1_002720-T1	transporter, putative	Medium	1	445	50.6	1769.55
BdWA1_000077-T1	Armadillo-type fold Armadillo-like helical Armadillo repeat-containing protein 6 Armadillo	Medium	1	2574	283.2	947.97

\* FDR (False discovery rate)

# Singh et al., Nature Microbiology 2023

**Table 2.** List of primer sequences for *Babesia* and species -specific PCRs.

<b>S. No.</b>	<b>Primer set</b>	<b>Forward primer</b>	<b>Reverse primer</b>
1	BdHSP70	TGAATGCGGGAGCTGGATGTAAG	TCAACACAGTCATGACACCACCAG
2	BdCelToS	ATGAAGTTCTTTTCCGTTTTATTCC	AAAGTCGTCGTCGTCTAGTG
3	BdV38-1	GTGGAGCTGGCAAAGTTCTC	TGGCATGAAAGGCCGCC
4	BmlTS	TCCATTGGGTTACGCTGG	CGTGCAGACAAACCCGCCTT
5	BmGPI12	CATAATCACTGCTTTCGCAG	CATCCACTCAGCACCAG
6	B. div AMA-1	CCAGAGGAAGGCAACAGTCCTC	CTGCATGGGCGTGAAGAGG
7	B. MO1 Helicase	TCGGAAGAATTCATCAAAC	AGTCGAAATGGACAAGGTC
8	<i>Babesia</i> 18S rRNA (736bp)	GAGGGCAAGTCTGGTGCCAGC	CCAGACAAATCACTCCACCAAC
9	B. common 18S rRNA (200bp)	GAGGGCAAGTCTGGTGCCAGC	CCAGACAAATCACTCCACCAAC

**Table 3.** List of PCR positive samples with identity scores to 18S rRNA of *Babesia* species genes from of Clade VI.

Sample ID	Gene description	Species	Percent Identity	Accession No.
LDB85	Small subunit ribosomal RNA gene (18S rRNA)	<i>Babesia odocoilei</i> isolate JC34	99.21	<a href="#">KY805843.1</a>
		<i>Babesia odocoilei</i> isolate JC09	99.21	<a href="#">KY805842.1</a>
		<i>Babesia capreoli</i> isolate GM19	99.21	<a href="#">KY805834.1</a>
		<i>Babesia sp. venatorum</i> isolate RD8	99.21	<a href="#">MG344777.1</a>
LDB139	Small subunit ribosomal RNA gene (18S rRNA)	<i>Babesia odocoilei</i> isolate JC34	98.52	<a href="#">KY805843.1</a>
		<i>Babesia odocoilei</i> isolate JC09	98.52	<a href="#">KY805842.1</a>
		<i>Babesia capreoli</i> isolate GM19	98.52	<a href="#">KY805834.1</a>
		<i>Babesia sp. venatorum</i> isolate RD8	98.52	<a href="#">MG344777.1</a>
FM1	Small subunit ribosomal RNA gene (18S rRNA)	<i>Babesia odocoilei</i> isolate JC34	98.04	<a href="#">KY805843.1</a>
		<i>Babesia odocoilei</i> isolate JC09	98.04	<a href="#">KY805842.1</a>
		<i>Babesia odocoilei</i> isolate YB73	98.04	<a href="#">KY805835.1</a>
		<i>Babesia sp. venatorum</i> isolate R30	98.04	<a href="#">MG062781.1</a>
FM7	Small subunit ribosomal RNA gene (18S rRNA)	<i>Babesia odocoilei</i> isolate JC34	100.00	<a href="#">KY805843.1</a>
		<i>Babesia odocoilei</i> isolate JC09	100.00	<a href="#">KY805842.1</a>
		<i>Babesia capreoli</i> isolate GM19 s	100.00	<a href="#">KY805834.1</a>
		<i>Babesia sp. venatorum</i> isolate RD8	100.00	<a href="#">MG344777.1</a>
FM8	Small subunit ribosomal RNA gene (18S rRNA)	<i>Babesia odocoilei</i> isolate JC34	100.00	<a href="#">KY805843.1</a>
		<i>Babesia odocoilei</i> isolate JC09	100.00	<a href="#">KY805842.1</a>
		<i>Babesia capreoli</i> isolate GM19	100.00	<a href="#">KY805834.1</a>
		<i>Babesia sp. venatorum</i> isolate R30	100.00	<a href="#">MG062781.1</a>
FM15	Small subunit ribosomal RNA gene (18S rRNA)	<i>Babesia odocoilei</i> isolate JC34	98.33	<a href="#">KY805843.1</a>
		<i>Babesia odocoilei</i> isolate JC09	98.33	<a href="#">KY805842.1</a>
		<i>Babesia capreoli</i> isolate GM19 s	98.33	<a href="#">KY805834.1</a>
		<i>Babesia sp. venatorum</i> isolate RD8	98.33	<a href="#">MG344777.1</a>